Description: Highlights of the Smaller Insurance Company Section's significant contributions at recent Society of Actuaries' events

Description: This document summarizes a meeting of the Reinsurance Section that occurred at the October 1982 Society of Actuaries annual Meeting in Washington D.C. The meeting consisted of a discussion related to the role and purpose of the section, a discussion of problems and pitfalls related to reinsurance treaties, and discussions related to choosing a reinsurer.

Description: In today’s market of post-pandemic consolidation and org chart streamlining, we’ve observed significant changes to actuarial career development and advancement opportunities. But, those changes aren’t occurring in equal measures across the arc of the actuarial career. Our focus is on the impact felt by experienced reinsurance actuaries.

Description: ReFocus is an annual global conference for senior-level life insurance and reinsurance executives hosted jointly by ACLI and the Society of Actuaries (SOA). This event features top-notch speakers, thought-provoking sessions, and superior networking opportunities.

Description: In this interview, Caroline Grégoire, formerly from Hannover Re, and now international mentor, coach, trainer and speaker, shares her views on how mentoring can support you on your career path and how it also benefits the reinsurance industry as a whole.

Description: In this webcast, presenters will outline the key content in ERM ASOPs 46, 47 and 55 and explore the impact each ASOP has on practitioners working in these fields. We will also describe the revision work currently under way in the ERM Committee of the Actuarial Standards Board.

Description: Chairperson's Corner from the March 2004 issue of Reinsurance News.

Description: This article reports on the latest annual survey about the relationship between reinsurers and their cedant clients. Some improvement was seen in 2011 from both actuaries and underwriters.

Description: An overview of reinsurance training class provided to the Bermuda Monetary Authority (Authority) and Central Bank of Trinidad and Tobago (Central Bank) covering all aspects of reinsurance. Article also provides an overview of initiatives that the two regulators (Authority and Central Bank) are involved with.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.